Rivaroxaban isopropylidene impurity reference substance and preparation method of reference substance

A technology of impurity reference substance, rivaroxaban, applied in the direction of organic chemistry, etc., to achieve the effect of simple process, simple preparation method and high purity

Active Publication Date: 2019-01-18
南京海辰药业股份有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] During the synthesis process of rivaroxaban according to the above route, a new isopropylidene impurity was found through impurity analysis. The impurity structure is shown in formula I. This impurity may be a process impurity of varoxaban medicine. The impurity and its synthesis have been reported in public information

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rivaroxaban isopropylidene impurity reference substance and preparation method of reference substance
  • Rivaroxaban isopropylidene impurity reference substance and preparation method of reference substance
  • Rivaroxaban isopropylidene impurity reference substance and preparation method of reference substance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] The preparation method of the rivaroxaban mesopropylidene impurity reference substance is as follows:

[0028] 1) Take 4.5g (15mmol) of 4-(4-(5-(aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone, add 6.4g (60mmol) Sodium carbonate and 50mL water were stirred until completely dissolved, 1.47g (15mmol) mesityl oxide was added, stirred at 25°C for 12 hours, extracted with dichloromethane, and spin-dried to obtain a white powdery solid, which was obtained by column chromatography 4-( 4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone.

[0029] figure 1 is 4-(4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3- The proton nuclear magnetic resonance spectrum figure of morpholinone intermediate, by figure 1 It can be seen that this example successfully synthesized 4-(4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl ) phenyl) -3-morpholinone intermediate.

[0030] 2) Add 0.1g (0.25mmol) 4...

Embodiment 2

[0034] The preparation method of the rivaroxaban mesopropylidene impurity reference substance is as follows:

[0035] 1) Take 4.5g (15mmol) of 4-(4-(5-(aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone, add 3.2g (30mmol) Sodium bicarbonate and 50mL of water were stirred until completely dissolved, 2.93g (30mmol) of mesityl oxide was added, stirred at 25°C for 12 hours, extracted with dichloromethane, and spin-dried to obtain a white powdery solid, which was obtained by column chromatography 4- (4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone .

[0036] figure 1 is 4-(4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3- The proton nuclear magnetic resonance spectrum figure of morpholinone intermediate, by figure 1 It can be seen that this example successfully synthesized 4-(4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl ) phenyl) -3-morpholinone intermediate.

[0037] 2) Add 0.1g (0...

Embodiment 3

[0041] The preparation of rivaroxaban isopropylidene impurity reference substance is as follows:

[0042] 1) Take 4.5g (15mmol) 4-(4-(5-(aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone, add 1.2g (30mmol) Sodium hydroxide and 50mL of water were stirred until they were completely dissolved, 2.93g (30mmol) of mesityl oxide was added, stirred at 25°C for 12 hours, extracted with dichloromethane, and spin-dried to obtain a white powdery solid, which was obtained by column chromatography 4- (4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone .

[0043] figure 1 is 4-(4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3- The proton nuclear magnetic resonance spectrum figure of morpholinone intermediate, by figure 1It can be seen that this example successfully synthesized 4-(4-(5-(((2-methyl-4-oxopent-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl ) phenyl) -3-morpholinone intermediate.

[0044] 2) Add 0.1g (0.25mmol)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a rivaroxaban isopropylidene impurity reference substance, and a structural formula of the impurity reference substance is shown in the specification. The invention also discloses a preparation method for the impurity reference substance, comprising the following steps: 4-(4-(5-(aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholine is reacted with mesityl oxide under basicconditions to obtain 4-(4-(5-(((2-methyl-4-oxypenta-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone; 4-(4-(5-(((2-methyl-4-oxypenta-2-yl)aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone is reacted with 5-chlorothiophene-2-formyl chloride under basic conditions to obtain the rivaroxaban isopropylidene impurity reference substance. The method provided by the invention achievesa simple process and high purity, and can provide qualified oxazolidine impurity reference substance for quality control of rivaroxaban.

Description

technical field [0001] The invention relates to pharmaceutical impurities, in particular to a rivaroxaban propylidene impurity reference substance and a preparation method thereof. Background technique [0002] Rivaroxaban (formula II) is an orally available, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as anticoagulant Blood enzyme III) to exert activity. Activation of factor X to factor Xa (FXa) through intrinsic and extrinsic pathways plays an important role in the blood coagulation cascade. [0003] [0004] The synthetic route of rivaroxaban is as follows: [0005] [0006] During the synthesis process of rivaroxaban according to the above route, a new isopropylidene impurity was found through impurity analysis. The impurity structure is shown in formula I. This impurity may be a process impurity of varoxaban medicine. This impurity and its synthesis have been reported in public infor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D413/14
CPCC07D413/14
Inventor 诸海滨任志远
Owner 南京海辰药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap